20.500.12556/DiRROS-29145 From biomarker discovery to clinical applications of metabolomics in glioblastoma Background/Objectives: In recent years, interest in studying changes in cancer metabolites has resulted in significant advances in the metabolomics field. Glioblastoma remains the most aggressive and lethal brain malignancy, which presents with notable metabolic reprogramming. Methods: We performed literature research from the PubMed database and considered research articles focused on the key metabolic pathways altered in glioblastoma (e.g., glycolysis, lipid metabolism, TCA cycle), the role of oncometabolites and metabolic plasticity, and the differential expression of metabolites in glioblastoma. Currently used metabolomics approaches can be either targeted, focusing on specific metabolites and pathways, or untargeted, which involves data-driven exploration of the metabolome and also results in the identification of new metabolites. Data processing and analysis is of great importance and can be improved with the integration of machine learning approaches for metabolite identification. Results: Changes in α/β-glucose, lactate, choline, and 2-hydroxyglutarate were detected in glioblastoma compared with non-tumor tissues. Different metabolites such as fumarate, tyrosine, and leucine, as well as citric acid, isocitric acid, shikimate, and GABA were detected in blood and CSF, respectively. Conclusions: Although promising new technological and bioinformatic approaches help us understand glioblastoma better, challenges associated with biomarker availability, tumor heterogeneity, interpatient variability, standardization, and reproducibility still remain. Metabolomics research, either alone or combined with genomics or proteomics (i.e., multiomics) in glioblastoma, can lead to biomarker identification, tracking of metabolic therapy response, discovery of novel metabolites and pathways, and identification of potential therapeutic targets. Omics metabolome multiomic integration tumor metabolic reprogramming biomarker diagnosis therapy precision oncology metabolom multiomska integracija presnovno reprogramiranje tumorja biološki označevalec dignoza terapija precizna onkologija true false true Angleški jezik Slovenski jezik Neznano 2026-04-22 10:45:18 2026-04-22 10:45:18 2026-04-23 04:02:12 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 9. 5. 2025; str. 1-24 no. 5, [article no.] 295 Vol. 15 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 577.2 2218-1989 10.3390/metabo15050295 235300099 RAZ_Samec_Neja_2025.pdf RAZ_Samec_Neja_2025.pdf 1 78363708F949437867BA396ADFE64E68 22163ceb4cdf8c4e693312fe7dbb8869f4fb416527273a9021009e876773ab1c cb3c4c8d-3e27-11f1-a343-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=43555 https://www.mdpi.com/2218-1989/15/5/295 1 9a420056-3e27-11f1-a343-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=43554 Univerzitetni klinični center Ljubljana 0 0 0